References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailComments on the discordant recommendations for the use of symptomatic slow acting drugs in knee osteoarthritis.
Reginster, Jean-Yves ULg; Cooper, Cyrus; Hochberg, Marc et al

in Current medical research and opinion (2015), 31(5), 1041-1045

Abstract Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent ... [more ▼]

Abstract Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of Symptomatic Slow-Acting Drugs in OsteoArthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation. [less ▲]

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailA 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial.
Langdahl, Bente L.; Teglbjaerg, Christence S.; Ho, Pei-Ran et al

in The Journal of clinical endocrinology and metabolism (2015), 100(4), 1335-1342

Context: One in 4 men in the US aged >50 will suffer an osteoporosis-related fracture. Less data are available on osteoporosis treatment in men than women. Objective: Evaluate denosumab therapy in men ... [more ▼]

Context: One in 4 men in the US aged >50 will suffer an osteoporosis-related fracture. Less data are available on osteoporosis treatment in men than women. Objective: Evaluate denosumab therapy in men with low BMD. Design: Phase 3 study with two treatment periods: a previously reported 12-month double-blind, placebo-controlled phase and a 12-month open-label phase. Setting: Multicenter in North America and Europe. Participants: 228 men entered the open-label phase and 219 completed the study. Intervention: Men from the original denosumab (long-term) and placebo (crossover) groups received denosumab 60 mg SC every 6 months. Main Outcome Measures: BMD, serum C-telopeptide (sCTX), and safety. Results: During the open-label phase, continued BMD increases occurred with long-term denosumab treatment (2.2% lumbar spine; 0.9% total hip; 1.3% femoral neck; 1.3% trochanter; and 0.2% 1/3 radius), resulting in cumulative 24-month gains from baseline of 8.0%, 3.4%, 3.4%, 4.6%, and 0.7%, respectively (all P<0.01). The crossover group showed BMD gains after 12 months of denosumab treatment similar to the long-term denosumab group during the first treatment year. Significant reductions in sCTX were observed following denosumab administration. Adverse events rates were similar between groups and no new safety signals identified. Conclusions: In men with low BMD, denosumab treatment for a second year continued to increase BMD, maintained reductions in bone resorption, and was well tolerated. BMD increased in men initiating denosumab during the second year. These effects were similar to those previously seen in postmenopausal women with osteoporosis and men with prostate cancer on androgen deprivation therapy. [less ▲]

Detailed reference viewed: 21 (3 ULg)
Full Text
Peer Reviewed
See detailLetter to the Editor.
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Seminars in arthritis and rheumatism (2015), 44(5), 15

Detailed reference viewed: 32 (19 ULg)
Full Text
Peer Reviewed
See detailBurden of frailty in the elderly population: perspectives for a public health challenge.
Buckinx, Fanny ULg; Rolland, Yves; Reginster, Jean-Yves ULg et al

in Archives of public health = Archives belges de sante publique (2015), 73(1), 19-25

Frailty is a major health condition associated with ageing. Although the concept is almost universally accepted, its operational definition remains controversial. Anyway, this geriatric condition ... [more ▼]

Frailty is a major health condition associated with ageing. Although the concept is almost universally accepted, its operational definition remains controversial. Anyway, this geriatric condition represents a huge potential public health issue at both the patient and the societal levels because of its multiple clinical, societal consequences and its dynamic nature. Here, we review existing definitions and assessment tools for frailty, we highlight consequences of this geriatric condition and we discuss the importance of its screening and prevention to limit its public health burden. [less ▲]

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailCan we identify patients with high risk of osteoarthritis progression who will respond to treatment ? A focus on epidemiology and phenotype of osteoarthritis
Bruyère, Olivier ULg; Cooper, C; Arden, N et al

in Drugs & Aging (2015), 32(3), 179-187

Osteoarthritis is a syndrome affecting a variety of patient profiles. A European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the European Union Geriatric Medicine ... [more ▼]

Osteoarthritis is a syndrome affecting a variety of patient profiles. A European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the European Union Geriatric Medicine Society working meeting explored the possibility of identifying different patient profiles in osteoarthritis. The risk factors for the development of osteoarthritis include systemic factors (e.g., age, sex, obesity, genetics, race, and bone density) and local biomechanical factors (e.g., obesity, sport, joint injury, and muscle weakness); most also predict disease progression, particularly joint injury, malalignment, and synovitis/effusion. The characterization of patient profiles should help to better orientate research, facilitate trial design, and define which patients are the most likely to benefit from treatment. There are a number of profile candidates. Generalized, polyarticular osteoarthritis and local, monoarticular osteoarthritis appear to be two different profiles; the former is a feature of osteoarthritis comorbid with inflammation or the metabolic syndrome, while the latter is more typical of post-trauma osteoarthritis, especially in cases with severe malalignment. Other biomechanical factors may also define profiles, such as joint malalignment, loss of meniscal function, and ligament injury. Early- and late-stage osteoarthritis appear as separate profiles, notably in terms of treatment response. Finally, there is evidence that there are two separate profiles related to lesions in the subchondral bone, which may determine benefit from bone-active treatments. Decisions on appropriate therapy should be made considering clinical presentation, underlying pathophysiology, and stage of disease. Identification of patient profiles may lead to more personalized healthcare, with more targeted treatment for osteoarthritis. [less ▲]

Detailed reference viewed: 18 (4 ULg)
Full Text
Peer Reviewed
See detailHow can we help implementing ESCEO alorith in real life?
Reginster, Jean-Yves ULg

in Osteoporosis International (2015), 26(1), 3

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailBaseline characteristics of the Liège hand osteoarthritis cohort (LIHOC)
Neuprez, Audrey ULg; Bruyère, Olivier ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(1), 305

Detailed reference viewed: 4 (1 ULg)
Full Text
Peer Reviewed
See detailAdded value of a triaxial accelerometer assessing gait parameters to predict falls and mortality among nursing home residents: A two-year prospective study.
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Technology and health care : official journal of the European Society for Engineering and Medicine (2015), 23

BACKGROUND: Gait impairment seems to be a risk factor for falls and mortality. Because gait change cannot be determined easily with classical clinical tests, some authors have suggested that it might be ... [more ▼]

BACKGROUND: Gait impairment seems to be a risk factor for falls and mortality. Because gait change cannot be determined easily with classical clinical tests, some authors have suggested that it might be useful to use a gait-analysis system among elderly community-dwelling people. OBJECTIVE: The main objective of the present study was to determine the predictive value of a quantitative evaluation of the gait characteristics in nursing home residents for the occurrence of falls and death performed using a tri-axial accelerometer (Locometrix(R)). MATERIAL AND METHODS: One hundred elderly nursing home residents (80 women and 20 men, mean age 86.4 +/- 6.04 years) were included in this study with the aim to follow them for 2 years. Deaths and falls were systematically recorded. A quantitative evaluation of a 10-second walk was performed with a tri-axial accelerometer (Locometrix(R)). Demographic data (i.e age, sex, body mass index) and clinical data (i.e. fall risk evaluated by the Tinetti test) were also recorded. RESULTS: During the two years of follow-up, 27 patients died. After adjustment on all potential confounding variables, only body mass index was significantly associated with the risk of mortality with an odds ratio of 0.86 (95% CI: 0.77-0.96, p=0.04). At the end of the study period, 440 falls had occurred (mean: 4.44 +/- 6.79 falls per patient) but no single factors were independently associated with fall incidence. CONCLUSION: Our results show that a quantitative gait analysis performed using a tri-axial accelerometer is not predictive of long-term falls and mortality among nursing home residents. [less ▲]

Detailed reference viewed: 12 (10 ULg)
Full Text
Peer Reviewed
See detailPrevalence of frailty in nursing home residents according to various diagnostic tools
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(1), 290

Detailed reference viewed: 23 (3 ULg)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Osteoporosis International (2015), 26(1), 268

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailHealth related quality of life in sarcopenia
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Osteoporosis International (2015), 26(1), 266

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailGrip fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Bautmans, I et al

in Osteoporosis International (2015), 26(1), 265

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailIs there a specific pattern of lean/fat mass ratio in sarcopenic subjects?
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Croisier, Jean-Louis ULg et al

in Osteoporosis International (2015), 26(1), 261

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailClinical components linked to sarcopenia: the sarcophage study
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in Osteoporosis International (2015), 26(1), 258

Detailed reference viewed: 23 (4 ULg)